Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
出版年份 2018 全文链接
标题
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
作者
关键词
CML, BCR-ABL1, Therapeutic strategies, Immunological approaches
出版物
Molecular Cancer
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-02-15
DOI
10.1186/s12943-018-0805-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
- (2017) C Schütz et al. LEUKEMIA
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- The HSP90 chaperone machinery
- (2017) Florian H. Schopf et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- New tricks for human farnesyltransferase inhibitor: cancer and beyond
- (2017) Jingyuan Wang et al. MedChemComm
- The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
- (2017) Muhammad Rauzan et al. PLoS One
- Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
- (2016) Elena Ceccacci et al. BRITISH JOURNAL OF CANCER
- Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells
- (2016) Yasufumi Matsuda et al. CANCER SCIENCE
- Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
- (2016) Fabio Stagno et al. Expert Review of Anticancer Therapy
- Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells
- (2016) WEI HE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting the mTOR Pathway in Leukemia
- (2016) Shira Dinner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- Protein prenylation: unique fats make their mark on biology
- (2016) Mei Wang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells
- (2015) ZI-JIE LONG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- GLI2 inhibition abrogates human leukemia stem cell dormancy
- (2015) Anil Sadarangani et al. Journal of Translational Medicine
- Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells
- (2015) C Riether et al. LEUKEMIA
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
- (2015) Giovanni Martinelli et al. Lancet Haematology
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation
- (2014) Michele Massimino et al. CARCINOGENESIS
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- Sirtuin inhibitors as anticancer agents
- (2014) Jing Hu et al. Future Medicinal Chemistry
- Do we need more drugs for chronic myeloid leukemia?
- (2014) Tessa L. Holyoake et al. IMMUNOLOGICAL REVIEWS
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
- (2014) J F Seymour et al. Blood Cancer Journal
- Immunology and Immunotherapy of Chronic Myeloid Leukemia
- (2014) Mette Ilander et al. Current Hematologic Malignancy Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
- (2013) Seiichi Okabe et al. CANCER BIOLOGY & THERAPY
- Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
- (2013) Seiichi Okabe et al. Cancer Cell International
- A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
- (2013) Daniel J. Goff et al. Cell Stem Cell
- Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
- (2013) Jorge E. Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Roles of SIRT1 in leukemogenesis
- (2013) WenYong Chen et al. CURRENT OPINION IN HEMATOLOGY
- BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein
- (2013) Pietro Buffa et al. FASEB JOURNAL
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
- (2013) Min Chen et al. JNCI-Journal of the National Cancer Institute
- Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
- (2013) Concetta Quintarelli et al. LEUKEMIA RESEARCH
- Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
- (2013) S. Stella et al. MOLECULAR CANCER THERAPEUTICS
- Correction: Characterization of PUD-1 and PUD-2, Two Proteins Up-Regulated in a Long-Lived daf-2 Mutant
- (2013) Yue-He Ding et al. PLoS One
- Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
- (2013) Susanne Badura et al. PLoS One
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
- (2013) K Airiau et al. Cell Death & Disease
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
- (2012) Ling Li et al. CANCER CELL
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Danusertib, an aurora kinase inhibitor
- (2012) Hielke J Meulenbeld et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
- (2012) F J Giles et al. LEUKEMIA
- Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1
- (2012) A R Soliera et al. LEUKEMIA
- Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor
- (2012) Manuela Mancini et al. LEUKEMIA RESEARCH
- SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells
- (2012) Z Wang et al. ONCOGENE
- Interferon and PV stem cells
- (2011) J. T. Prchal BLOOD
- Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
- (2011) H. Yuan et al. BLOOD
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
- (2011) Jorge Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
- (2011) Bing Long et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
- (2011) E Traer et al. LEUKEMIA
- Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
- (2011) E K Allan et al. LEUKEMIA
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
- (2011) Y Kuwatsuka et al. Blood Cancer Journal
- Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
- (2010) R. Tanaka et al. BLOOD
- K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
- (2010) B. D. Smith et al. CLINICAL CANCER RESEARCH
- WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
- (2010) Yusuke Oji et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Critical molecular pathways in cancer stem cells of chronic myeloid leukemia
- (2010) Y Chen et al. LEUKEMIA
- Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
- (2010) Monica Bocchia et al. Nature Reviews Clinical Oncology
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease
- (2009) Nitin Jain et al. CANCER
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein
- (2009) Manuela Mancini et al. LEUKEMIA RESEARCH
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
- (2008) A. Gontarewicz et al. BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
- (2008) Hugues de Lavallade et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
- (2008) Ji Wu et al. JNCI-Journal of the National Cancer Institute
- Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
- (2008) L X Wu et al. LEUKEMIA
- Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond
- (2008) J. V. Melo et al. Hematology-American Society of Hematology Education Program
- Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis
- (2007) Fabio Stagno et al. LEUKEMIA RESEARCH
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now